Categories: Healthcare

Large Volume Parenteral (LVP) Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Large Volume Parenteral (LVP) Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Large Volume Parenteral (LVP) Market:

https://www.thebusinessresearchcompany.com/report/large-volume-parenteral-lvp-global-market-report

According to The Business Research Company’s Large Volume Parenteral (LVP) Global Market Report 2024, The large volume parenteral (lvp) market size has grown strongly in recent years. It will grow from $11.42 billion in 2023 to $12.44 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, growth in the aging population, rising demand for sterile pharmaceuticals, expansion of healthcare infrastructure, development of regulatory frameworks for pharmaceuticals.

The large volume parenteral (lvp) market size is expected to see strong growth in the next few years. It will grow to $17.35 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growing demand for biologics and biosimilars, rising healthcare expenditure, expansion of pharmaceutical outsourcing, increasing focus on personalized medicine, globalization of pharmaceutical supply chains. Major trends in the forecast period include technological advancements in manufacturing processes, integration of advanced technologies in pharmaceutical production, implementation of single-use technologies, development of high-concentration formulations, rise in 3d printing applications for pharmaceuticals.

The growing prevalence of chronic diseases is expected to propel the growth of the large-volume parenteral market going forward. Chronic diseases refer to a sickness or condition that typically lasts three months or longer and can potentially worsen over time. The rise in chronic diseases is mainly driven by tobacco use, being around smoke, and poor nutrition. These patients must require an appropriate ratio of essential nutrients that support the maintenance of strength, and the parenteral mode of administration facilitates the correct pharmaceutical dosage because most of the drug is directly absorbed in circulation, skipping the digestive system. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that in the US by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising from 71.522 million in 2020 to 142.66 million. Therefore, the growing prevalence of chronic diseases drives the growth of the large-volume parenteral market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12195&type=smp

The large volume parenteral (lvp) market covered in this report is segmented –

1) By Type: Soft Bag LVP, Plastic Bag LVP, Glass Bottle LVP

2) By Volume: 100 ML – 250 ML, 250 ML – 500 ML, 500 ML – 1000 ML, 1000 ML -2000 ML, 2000 And More

3) By Application: Basic Infusion, Therapeutics Infusion, Nutritious Infusion

4) By End-User: Hospital, Medical Centers, Other End Users

Product innovation has emerged as a key trend gaining popularity in the large-volume parenteral market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in March 2022, SGD Pharma SA, a France-based producer of molded and tubular glass for pharmaceutical primary packaging company, launched 100-ml type I molded glass vials that are sterile and ready for aseptic filling and finishing of parenteral medicinal formulations. It helps to prevent vial scratches, supports the visual examination of the filled vial, and lowers the likelihood of rejection at quality control.

The large volume parenteral (lvp) market report table of contents includes: